Die for Johnson! Aberdeen's $21 billion marriage to pharmacyclics

Source: Biovalley 2015-03-05 March 5, 2015 news, the financial times (FT) just revealed that Johnson & Johnson is about to buy partner pharmacyclics with more than $17 billion, here abbvie announced that it will buy pharmacyclics with about $21 billion to enhance its oncology drug pipeline (related reading: a product costs $17 billion?! The deal will consist of 58% of cash and 42% of abbvie's common stock, Abercrombie said in a statement Pharmacyclics shareholders can choose cash, abbvie shares or a combination of the two In the cash segment, Aberdeen will pay $261.25 a share, a 13% premium to the closing price of pharmaceuticals on NASDAQ on Wednesday Abbvie said it hopes to complete the acquisition through a combination of existing funds and new debt and equity Richard Gonzalez, chief executive of Aberdeen, said in a statement that imbruvica, a breakthrough anticancer drug developed by pharmacics, not only perfectly complements the company's Oncology pipeline, but also has a strong clinical effect on a wide range of hematological malignancies At present, imbruvica has been approved for four types of blood cancer in the United States and three types of blood cancer in Europe Earlier this year, pharmaceuticals said that imbruvica's sales in the U.S market are expected to reach $10 billion this year In 2011, Johnson & Johnson and pharmacyclics signed a nearly US $1 billion cooperation to jointly develop imbruvica (ibrutinib), which is the first oral Burton tyrosine kinase (Btk) inhibitor, and plays an anti-cancer role by inhibiting the Burton tyrosine kinase (Btk) required by tumor cell replication and metastasis For quite a long time, large pharmaceutical companies signed more partnership with smaller pharmaceutical companies, which is conducive to the joint development of products, rather than the acquisition of small companies as a whole However, in recent years, with the increasingly fierce competition in the industry, this way has gradually been replaced by the form of "big fish eat small fish" or even "big fish eat big fish"